Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AbCellera Biologics Inc.

< Previous 1 2 3 Next >
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Participate at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q1 2025 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Participate at Upcoming Investor Conferences in May and June
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Full Year 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Participate at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at Upcoming Investor Conferences in December and January
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q3 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at Upcoming Investor Conferences in November 2024
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Present at Upcoming Investor Conferences in September
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera Reports Q2 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
From AbCellera Biologics Inc.
Via Business Wire
Tickers ABCL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.